Exogenus Therapeutics
Pedro Vilarinho is a seasoned professional with extensive experience in technology entrepreneurship and innovation. Currently serving as General Manager at HiSeedTech since September 2017, Vilarinho contributes to fostering value creation through technology and open innovation in a not-for-profit setting. Vilarinho also holds the position of Chief Business Development Officer at Rya Purification Technologies and serves as a TEC Faculty member at Porto Business School. Additionally, Vilarinho is a Board Member for Exogenus Therapeutics, Pharma73, and Extremochem. Previous roles include Assistant Professor at Universidade de Aveiro and CEO of Act at COTEC, where Vilarinho led initiatives in entrepreneurship and technology commercialization. Vilarinho's academic background includes a PhD in Industrial Engineering from Universidade do Porto, an MSc in Computer Science from Universidade de Coimbra, and an undergraduate degree in Electronics and Telecommunications Engineering from Universidade de Aveiro.
This person is not in any teams
Exogenus Therapeutics
Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‑CoV‑2 infection. Contact us at team@exogenus-t.com